News
- AlphaMed receives $750,000 grant to continue development of a bismuth-212/lead-212/lead-203 therapy and imaging drug for treating metastatic melanoma. (May 6, 2008) The lead-212/bismuth-212 radionuclide generators are prepared at PNNL.
- PNNL teams with Advanced Medical Isotopes Corporation on isotope production optimization calculations. (August 22, 2007)
- Dennis W. Wester named Radioisotopes Program Lead Scientist (June 15, 2007)
- AlphaMed and Pacific Northwest National Laboratory enter into a commercial work-for-others contract to continue processing uranium-232 to produce radium-224/lead-212 generators used in cancer treatment research (May 2, 2007).
- Darrell Fisher appointed to NRC Advisory Committee on Medical Uses of Isotopes (February 27, 2007)
- Darrell Fisher selected as Scientific Director, Office of National Isotope Programs (January 16, 2007).
- Darrell Fisher elected Treasurer-elect of the Health Physics Society (January 2, 2007).
- IsoRay Medical, Inc., and PNNL win 2006 R&D 100 Award for cesium-131 brachytherapy seed, recognized by R&D Magazine as one of the most important achievements in cancer treatment in nearly 20 years. (July 10, 2006) PNNL announcement
- IsoRay Medical, Inc., and PNNL win 2006 Federal Laboratory Consortium (FLC) award for cesium-131 brachytherapy seed, recognizes outstanding work in transferring technology from a federal laboratory to the marketplace. (May 3, 2006) PNNL announcement
- IsoRay and PNNL team on Cs-131 seed production for cancer treatment (November 7, 2005)
- IsoRay inaugurates new facility for Cs-131 brachytherapy seed production in Richland (November 4, 2005)
- IsoRay Seeks to Produce Cesium-131 at Idaho National Laboratory. Cs-131 seed manufacturing for IsoRay continues at PNNL; over 90 patients treated for prostate cancer. (October 12, 2005)
- Lead-212 and Bismuth-212 Successful in Treating Melanoma. Radioisotope generators made at PNNL for AlphaMed, Inc., support preclinical studies in mice on therapy of melanoma at the University of Missouri-Columbia using Pb-212-peptides; alpha radiation key to achieving complete remissions, reported in the medical journal Clinical Cancer Research, vol. 11(15), pages 5616-5621. (August 1, 2005)
- PNNL Radioisotopes Program Supplies Cesium-137 to Isotope Products Laboratories for Manufacture of Cs-137 Brachytherapy Sources. The Cs-137 tubes (12 to 100 mCi each) are used at medical centers to treat cervical and ovarian cancer; recent availability of Cs-137 re-establishes the supply of these devices. (June 15, 2005)
- Cesium-131 seeds used in first patient; PNNL Radioisotopes Program helps IsoRay Medical achieve major advance in seed implant brachytherapy against prostate cancer (October 26, 2004)
- First cancer patient to be treated with new cesium-131 seeds at the University of Washington (October 26, 2004)
- IsoRay Medical, signs contract with PNNL and DOE to produce cesium-131 brachytherapy seeds for treating prostate cancer (May 12, 2004)
- PNNL scientists to receive 2004 American Chemical Society Award for developing injectable radiogels for high-dose therapy of cancer -- to be presented at the 59th Northwest/18th Rocky Mountain Regional Industrial Innovation Awards Program, Utah State University, Logan, Utah, on June 7, 2004 (announced April 13, 2004)
- PNNL wins a 2004 Federal Laboratory Consortium Award for outstanding achievement in transferring technology to the commercial marketplace. Sharing in this award are Dr. Darrell Fisher (program lead), Dr. Oleg Egorov (Fundamental Sciences Directorate), Dr. Eric Lund (Economic Development and Commercialization Office), and Mr. Ken Givens representing MedActinium, Inc., Knoxville, TN. (March 1, 2004)
- Radioisotopes Program to work with Theragenics, Inc. and Isotek on extraction of actinium-225 (October 16, 2003)
- DOE awards $128M D&D contract to Isotek Systems to extract thorium-229 for cancer isotope production; PNNL to provide key technology to produce and deliver actinium-225 (October 9, 2003)
- AlphaMed wins $500K cancer grant for alpha therapy against melanoma; PNNL helps with Bi-212 generators and dosimetry (August 13, 2003)
- IsoRay Medical, receives Food and Drug Administration approval for market and sale of advanced cesium-131 prostate cancer seed (March 28, 2004) [PDF]
- Radioisotopes Program Lead, Darrell Fisher, honored as Fellow of the Health Physics Society (June 6, 2003)
- Radioisotopes Program Scientist, Lane Bray, with 24 U.S. patents, honored as Battelle "Distinguished Inventor" (April 21, 2003) [PDF 171KB]
- Actinium Pharmaceuticals and Department of Energy's Pacific Northwest National Laboratory Announce Collaboration to Support Development of a Novel Cancer Treatment (January 29, 2003). [PDF 66KB]
- AlphaMed Announces Shipment of its Unique Cancer-Treatment Radioisotope (December 19, 2002).
- U.S. Patent Awarded for Cobalt-57 Flood Source Design (December 3, 2002).
- PNNL Radioisotopes Program Picking Up Steam (December 2, 2002).
- AlphaMed Works with Pacific Northwest National Laboratory on Radioisotope Production and Distribution
- AlphaMed and Pacific Northwest National Laboratory enter into a Cooperative Research and Development Agreement for the Processing of U-232 in the Production of Ra-224/Pb-212/Bi-212 generators (August 27, 2002).
- PNNL Radioisotopes Program helps small business expand opportunities in nuclear medicine (June 28, 2002)
